感染

订阅

MedSci主页 / 所有栏目 / 感染

IDWeek 2020：默克公司将展示其广泛的抗感染药物研发管线

2020-10-22 Allan MedSci原创

HIV-1呼吸机相关细菌性肺炎HABP / VABPDELSTRIGOPIFELTRO
关注

默克公司今天宣布，其广泛的传染病和疫苗计划的临床数据将于2020年10月21日至25日在IDWeek 2020上发表。

默克公司今天宣布，其广泛的传染病和疫苗计划的临床数据将于2020年10月21日至25日在IDWeek 2020上发表。

这些临床数据包括来自RESTORE-IMI 2的新亚组分析，该试验评估了RECARBRIO™（亚胺培南、西司他丁和雷巴坦）在患有医院获得性或呼吸机相关细菌性肺炎（HABP / VABP）的成年人患者中的安全性和有效性，以及PIFELTRO™（doravirine）或DELSTRIGO™（doravirine / lamivudine / tenofovir disoproxil fumarate）在未接受过抗HIV-1治疗的50岁及以上成年患者中安全性和有效性。作为默克致力于更好地了解传染病的承诺的一部分，默克研究人员将提供流行病学数据。

默克传染病和疫苗研究实验室高级副总裁Nicholas Kartsonis博士说：“今年，我们所有人都目睹了传染病可能对患者和社会造成的毁灭性影响。这种大流行迫切需要默克公司继续致力于通过研究应对传染病威胁的承诺”。

 

原始出处：

https://www.firstwordpharma.com/node/1767149?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1822551, encodeId=17ec1822551c9, content=<a href='/topic/show?id=41311033568e' target=_blank style='color:#2F92EE;'>#默克公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103356, encryptionId=41311033568e, topicName=默克公司)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Mar 19 20:43:34 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273951, encodeId=223012e3951a3, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300432, encodeId=c48e13004329a, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301499, encodeId=a4d413014998a, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893898, encodeId=4ab0893898ef, content=学习了，真心赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662320561, createdName=1224b7dam06(暂无昵称), createdTime=Fri Oct 23 07:42:17 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
    2021-03-19 mgqwxj

    #默克公司#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1822551, encodeId=17ec1822551c9, content=<a href='/topic/show?id=41311033568e' target=_blank style='color:#2F92EE;'>#默克公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103356, encryptionId=41311033568e, topicName=默克公司)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Mar 19 20:43:34 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273951, encodeId=223012e3951a3, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300432, encodeId=c48e13004329a, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301499, encodeId=a4d413014998a, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893898, encodeId=4ab0893898ef, content=学习了，真心赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662320561, createdName=1224b7dam06(暂无昵称), createdTime=Fri Oct 23 07:42:17 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
    2020-10-24 makuansheng

    #默克#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1822551, encodeId=17ec1822551c9, content=<a href='/topic/show?id=41311033568e' target=_blank style='color:#2F92EE;'>#默克公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103356, encryptionId=41311033568e, topicName=默克公司)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Mar 19 20:43:34 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273951, encodeId=223012e3951a3, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300432, encodeId=c48e13004329a, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301499, encodeId=a4d413014998a, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893898, encodeId=4ab0893898ef, content=学习了，真心赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662320561, createdName=1224b7dam06(暂无昵称), createdTime=Fri Oct 23 07:42:17 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
    2020-10-24 lqvr

    #研发#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1822551, encodeId=17ec1822551c9, content=<a href='/topic/show?id=41311033568e' target=_blank style='color:#2F92EE;'>#默克公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103356, encryptionId=41311033568e, topicName=默克公司)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Mar 19 20:43:34 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273951, encodeId=223012e3951a3, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300432, encodeId=c48e13004329a, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301499, encodeId=a4d413014998a, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893898, encodeId=4ab0893898ef, content=学习了，真心赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662320561, createdName=1224b7dam06(暂无昵称), createdTime=Fri Oct 23 07:42:17 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
    2020-10-24 huirong

    #药物研发#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1822551, encodeId=17ec1822551c9, content=<a href='/topic/show?id=41311033568e' target=_blank style='color:#2F92EE;'>#默克公司#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103356, encryptionId=41311033568e, topicName=默克公司)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Fri Mar 19 20:43:34 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273951, encodeId=223012e3951a3, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300432, encodeId=c48e13004329a, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301499, encodeId=a4d413014998a, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Sat Oct 24 01:43:34 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893898, encodeId=4ab0893898ef, content=学习了，真心赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f662320561, createdName=1224b7dam06(暂无昵称), createdTime=Fri Oct 23 07:42:17 CST 2020, time=2020-10-23, status=1, ipAttribution=)]
    2020-10-23 1224b7dam06(暂无昵称)

    学习了，真心赞

    0

相关资讯

吉利德科学：长效HIV-1衣壳抑制剂Lenacapavir（GS-6207）临床表现良好

吉利德科学公司今日公布了一项正在进行的1期临床研究的最新数据，结果表明，研究性HIV-1衣壳功能抑制剂Lenacapavir（GS-6207）在单次900毫克剂量给药后，预期的治疗浓度至少持续6个月。

FDA批准PrEP预防性疗法Descovy，以减少性传播感染HIV-1风险

美国食品药品监督管理局（FDA）已批准将吉利德（Gilead Sciences）的暴露前预防疗法（PrEP）Descovy（恩曲他滨200mg和替诺福韦alafenamide 25mg）药物用于有HIV感染风险的成年人，减少性传播感染HIV-1的风险。该药物需每日服用。

mSphere：HIV疫苗接种对HIV感染后抗体反应的影响

对突破性HIV-1感染的分析可以阐明之前的疫苗接种是否会激发相关的免疫反应。在这里，我们测量了14名南非志愿者的HIV特异性抗体反应，他们在参加含包膜免疫原的1/2期试验后感染了HIV。

LANCET INFECT DIS：1990 - 2015全球和区域HIV-1分子流行病学特征

HIV-1 · 2019-02-02

-->

NEJM：Fostemsavir治疗多药耐药性HIV感染者

HIV融合抑制剂Fostemsavir可显著减少多药耐药HIV感染患者血液RNA水平

Nat Med：抗HIV-1抗体联合治疗与病毒特异性T细胞免疫力增强相关

联合抗逆转录病毒疗法（ART）在控制人类免疫缺陷病毒（HIV）-1方面非常有效，但由于存在潜伏的病毒库，需要终身服药。强效的广谱中和抗体（bNAbs）代表了一种潜在的替代或辅助ART。除了抑制病毒血症

拓展阅读

FDA批准默沙东的抗生素组合Recarbrio，治疗细菌性肺炎

默沙东的抗生素组合Recarbrio（亚胺培南-西司他丁/雷巴坦），获得FDA批准，用于治疗医院获得性细菌性肺炎（HABP）和呼吸机相关细菌性肺炎（VABP）的18岁及以上患者。